Cor Vasa 2020, 62(5):457-460 | DOI: 10.33678/cor.2019.062

(Use of intracoronary epinephrine in a patient with noflow phenomenon in cardiogenic shock - case report)

Milan Dragula, Ivana Ságová, Miloš Kňazeje, Jurina Sadloňová
I. interná klinika, Univerzitná nemocnica a Jesseniova lekárska fakulta v Martine, Univerzita Komenského v Bratislave, Martin, Slovensko

Early reperfusion therapy in ST elevation myocardial infraction (STEMI) has been consistently shown to improve outcome. Despite early reperfusion therapy it has been reported that in a significant number of pa- tients cardiac tissue fails to perfuse normally despite opening of the occluded coronary vessel. This is known as noflow phenomenon and today remains an elusive therapeutic target. The presence of noflow is a serious prognostic sign. Noflow can result in poor healing of the infarct and adverse left ventricular remodeling, increasing the risk of major adverse cardiac events, including congestive heart failure and death. In our case we describe a 58-year-old patient with cardiogenic shock due to acute myocardial infarction, with the presence of noflow after percutaneous coronary intervention (PCI), successfully treated with intracoronary epinephrine. Kľúčové slová: Akútny infarkt myokardu Intrakoronárny adrenalín Noflow fenomén Perkutánna koronárna intervencia

Keywords: Acute myocardial infarction, Intracoronary epinephrine, Noflow phenomenon, Percutaneous coronary intervention

Received: August 11, 2019; Accepted: August 28, 2019; Published: November 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dragula M, Ságová I, Kňazeje M, Sadloňová J. (Use of intracoronary epinephrine in a patient with noflow phenomenon in cardiogenic shock - case report). Cor Vasa. 2020;62(5):457-460. doi: 10.33678/cor.2019.062.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kloner RA, Ganote CE, Jennings RB. The "noreflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974;54:1496-506. Go to original source... Go to PubMed...
    2. Rezkalla SH, Stankowski RV, Hanna J, et al. Management of No-Reflow Phenomenon in the Catheterization Laboratory. JACC Cardiovasc Interv 2017;10:215-223. Go to original source... Go to PubMed...
    3. Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J 2016;37:1024-1033. Go to original source... Go to PubMed...
    4. Aksu T, Guler TE, Colack A, et al. Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: a retrospective study. BMC Cardiovasc Disord 2015;15:10. Go to original source... Go to PubMed...
    5. Skelding KA, Goldstein JA, Mehta L, et al. Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv 2002;57:305-309. Go to original source... Go to PubMed...
    6. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119-177. Go to original source... Go to PubMed...
    7. Galiuto L. Optimal therapeutic strategies in the setting of post- -infarct no reflow: the need for a pathological classification. Heart 2004;90:123-125. Go to original source... Go to PubMed...
    8. Malmberg K, Rydén L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65. Go to original source... Go to PubMed...
    9. Di Carli NF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 2003;41:1387-1393. Go to original source... Go to PubMed...
    10. Iwakura K, Ito H, Ikushima M, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003;41:1-7. Go to original source... Go to PubMed...
    11. Li XD, Yang YJ, Hao YC, et al. Effects of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention: a meta analysis. Chin Med J (Engl) 2013;126:1755-1760. Go to PubMed...
    12. Mancini JG, Filion KB, Windle SB, et al. Meta-analysis of the long-term effect of routine aspiration thrombectomy in patients undergoing primary percutaneous coronary intervention. Am J Cardiol 2016;118:23-31. Go to original source... Go to PubMed...
    13. Maddury J, Nemani L. No-Reflow. Ind J Car Dis Wom 2017;2:82-98. Go to original source...
    14. Forman MB, Jackson EK. Importance of tissue perfusion in ST segment elevation myocardial infarction patients undergoing reperfusion strategies: role of adenosine. Clin Cardiol 2007;30:583-585. Go to original source... Go to PubMed...
    15. Forman MB, Stone GW, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev 2006;24:116-147. Go to original source... Go to PubMed...
    16. Forman MB, Hou D, Jackson EK. Treating Acute "No-Reflow" with Intracoronary Adenosine. Tex Heart Inst J 2008;35: 439-446.
    17. Nazir SA, Khan JN, Mahmoud IZ, et al. The REFLO-STEMI (REperfusion Facilitated by LOcal adjunctive therapy in ST-Elevation Myocardial Infarction) trial: a randomised controlled trial comparing intracoronary administration of adenosine or sodium nitroprusside with control for attenuation of microvascular obstruction during primary percutaneous coronary intervention. Southampton (UK): NIHR Journals Library; 2016 Dec. PMID: 27929619. Go to original source...
    18. Parham WA, Bouhasin A, Ciaramita JP. Coronary hyperemic dose responses of intracoronary sodium nitroprusside. Circulation 2004;109:1236-1243. Go to original source... Go to PubMed...
    19. Su Q, Li L, Naing KA, Sun Y. Safety and effectiveness of nitroprusside in preventing no-reflow during percutaneous coronary intervention: a systematic review. Cell Biochem Biophys 2014;68:201-206. Go to original source... Go to PubMed...
    20. Zhao S, Qi G, Tian W, et al. Effect of intracoronary nitroprusside in preventing no reflow phenomenon during primary percutaneous coronary intervention: a meta-analysis. J Interv Cardiol 2014;27:356-364. Go to original source... Go to PubMed...
    21. Wang L, Cheng Z, Gu Y, Peng D. Short-term effects of verapamil and diltiazem in the treatment of no reflow phenomenon: a meta-analysis of randomized controlled trials. Biomed Res Int 2015;2015:382086. Go to original source... Go to PubMed...
    22. Huang R, Patel P, Walinsky P. Efficacy of intracoronary nicardipine in the treatment of no-reflow during PCI. Catheter Cardiovasc Interv 2006;68:671-676. Go to original source... Go to PubMed...
    23. Iwakura J, Ito H, Okamura A. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. Circ J 2009;73:925-931. Go to original source... Go to PubMed...
    24. Wu M, Huang Z, Xie H, Zhou Z. Nicorandil in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis. PLoS One 2013;8:e78231. Go to original source... Go to PubMed...
    25. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019;40:87-165. Go to original source... Go to PubMed...
    26. Vítovec J, Špinar J, et al. Farmakoterapie kardiovaskulárních onemocnění. 2. vydání. Praha: Grada Publishing, a.s, 2004:248.
    27. Barbato E. Role of adrenergic receptors in human coronary vasomotion. Heart 2009;95:603-608. Go to original source... Go to PubMed...
    28. Zhang ZP, Su X, Yang YC, et al. Cardiac arrest with coronary artery spasm: does the use of epinephrine during cardiopulmonary arrest exacerbate the spasm? Am J Emerg Med 2015;33:479.e5-479.e6. Go to original source... Go to PubMed...
    29. Choi JH, Chun KJ, Lee SH, et al. Usefulness of Intracoronary Epinephrine in Severe Hypotension during Percutaneous Coronary Interventions. Korean Circ J 2013;43:739-743. Go to original source... Go to PubMed...
    30. The RESTORE-SIRIO Randomized Controlled Trial (RESTORE-SIRIO), 2016, February. Dostupné z: https://clinicaltrials.gov.
    31. Malik V, Safaa A, Clugston R, et al. How should I treat this unusual anterolateral ST-elevation myocardial infarction with recurrent ventricular fibrillation and cardiac arrest? EuroIntervention 2016;12:928-932. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes